Latest Cormorant Asset Management, LP Stock Portfolio
Cormorant Asset Management, LP Performance:
2025 Q3: 21.99%YTD: 0.96%2024: -1.93%
Performance for 2025 Q3 is 21.99%, and YTD is 0.96%, and 2024 is -1.93%.
About Cormorant Asset Management, LP and 13F Hedge Fund Stock Holdings
Cormorant Asset Management, LP is a hedge fund based in BOSTON, MA. On 31-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $3.1 Billions. In it's latest 13F Holdings report, Cormorant Asset Management, LP reported an equity portfolio of $1.4 Billions as of 30 Sep, 2025.
The top stock holdings of Cormorant Asset Management, LP are , , EYPT. The fund has invested 14.3% of it's portfolio in BRIDGEBIO ONCOLOGY THERAPEUT and 11.4% of portfolio in ABIVAX SA.
The fund managers got completely rid off MERUS N V (MRUS), VERONA PHARMA PLC (VRNA) and HELIX ACQUISITION CORP II stocks. They significantly reduced their stock positions in MOONLAKE IMMUNOTHERAPEUTICS (MLTX), JANUX THERAPEUTICS INC (JANX) and PRAXIS PRECISION MEDICINES I (PRAX). Cormorant Asset Management, LP opened new stock positions in BRIDGEBIO ONCOLOGY THERAPEUT and AMYLYX PHARMACEUTICALS INC (AMLX). The fund showed a lot of confidence in some stocks as they added substantially to MBX BIOSCIENCES INC and AVIDITY BIOSCIENCES INC (RNA).
The top stock holdings of Cormorant Asset Management, LP are , , EYPT. The fund has invested 14.3% of it's portfolio in BRIDGEBIO ONCOLOGY THERAPEUT and 11.4% of portfolio in ABIVAX SA.
The fund managers got completely rid off MERUS N V (MRUS), VERONA PHARMA PLC (VRNA) and HELIX ACQUISITION CORP II stocks. They significantly reduced their stock positions in MOONLAKE IMMUNOTHERAPEUTICS (MLTX), JANUX THERAPEUTICS INC (JANX) and PRAXIS PRECISION MEDICINES I (PRAX). Cormorant Asset Management, LP opened new stock positions in BRIDGEBIO ONCOLOGY THERAPEUT and AMYLYX PHARMACEUTICALS INC (AMLX). The fund showed a lot of confidence in some stocks as they added substantially to MBX BIOSCIENCES INC and AVIDITY BIOSCIENCES INC (RNA).
Cormorant Asset Management, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Cormorant Asset Management, LP made a return of 21.99% in the last quarter. In trailing 12 months, it's portfolio return was -2.17%.
New Buys
| Ticker | $ Bought |
|---|---|
| bridgebio oncology therapeut | 207,034,000 |
| oruka therapeutics inc | 10,256,100 |
| amylyx pharmaceuticals inc | 6,795,000 |
New stocks bought by Cormorant Asset Management, LP
Additions
| Ticker | % Inc. |
|---|---|
| mbx biosciences inc | 75.00 |
| avidity biosciences inc | 50.00 |
| rapport therapeutics inc | 8.56 |
Additions to existing portfolio by Cormorant Asset Management, LP
Reductions
| Ticker | % Reduced |
|---|---|
| moonlake immunotherapeutics | -76.52 |
| janux therapeutics inc | -43.33 |
| praxis precision medicines i | -38.46 |
| arcutis biotherapeutics inc | -22.5 |
| insmed inc | -20.37 |
| bridgebio pharma inc | -12.5 |
| abivax sa | -8.45 |
| centessa pharmaceuticals plc | -7.74 |
Cormorant Asset Management, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| cargo therapeutics inc | -13,930,900 |
| helix acquisition corp ii | -30,893,600 |
| vyne therapeutics inc | -2,262,050 |
| merus n v | -58,912,000 |
| ars pharmaceuticals inc | -19,195,000 |
| aardvark therapeutics inc | -10,818,600 |
| kala bio inc | -2,870,410 |
| verona pharma plc | -33,103,000 |
Cormorant Asset Management, LP got rid off the above stocks
Sector Distribution
Cormorant Asset Management, LP has about 50.7% of it's holdings in Others sector.
| Sector | % |
|---|---|
| Others | 50.7 |
| Healthcare | 49.3 |
Market Cap. Distribution
Cormorant Asset Management, LP has about 4.3% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 54.9 |
| SMALL-CAP | 24.7 |
| MID-CAP | 15.2 |
| LARGE-CAP | 4.3 |
Stocks belong to which Index?
About 35.1% of the stocks held by Cormorant Asset Management, LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 64.9 |
| RUSSELL 2000 | 35.1 |
Cormorant Asset Management, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Cormorant Asset Management, LP
Cormorant Asset Management, LP has 36 stocks in it's portfolio. About 67.3% of the portfolio is in top 10 stocks. MLTX proved to be the most loss making stock for the portfolio. was the most profitable stock for Cormorant Asset Management, LP last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 4.39 | 775,000 | 63,627,500 | reduced | -3.12 | ||
| AMLX | amylyx pharmaceuticals inc | 0.47 | 500,000 | 6,795,000 | new | |||
| ARQT | arcutis biotherapeutics inc | 1.01 | 775,000 | 14,608,800 | reduced | -22.5 | ||
| AXSM | axsome therapeutics inc | 0.84 | 100,000 | 12,145,000 | unchanged | 0.00 | ||
| BBIO | bridgebio pharma inc | 5.02 | 1,400,000 | 72,716,000 | reduced | -12.5 | ||
| BMEA | biomea fusion inc | 0.50 | 3,570,870 | 7,213,160 | unchanged | 0.00 | ||
| CABA | cabaletta bio inc | 0.81 | 5,000,000 | 11,700,000 | unchanged | 0.00 | ||
| CNTA | centessa pharmaceuticals plc | 3.22 | 1,925,000 | 46,681,200 | reduced | -7.74 | ||
| CRBP | corbus pharmaceuticals hldgs | 2.07 | 2,375,000 | 30,043,800 | unchanged | 0.00 | ||
| CRNX | crinetics pharmaceuticals in | 1.15 | 400,000 | 16,660,000 | unchanged | 0.00 | ||
| EWTX | edgewise therapeutics inc | 4.49 | 4,010,000 | 65,042,200 | reduced | -5.69 | ||
| EYPT | eyepoint pharmaceuticals inc | 8.18 | 8,325,000 | 118,548,000 | unchanged | 0.00 | ||
| INSM | insmed inc | 4.27 | 430,000 | 61,924,300 | reduced | -20.37 | ||
| JANX | janux therapeutics inc | 1.43 | 850,000 | 20,774,000 | reduced | -43.33 | ||
| KALA | kala bio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MLTX | moonlake immunotherapeutics | 0.99 | 1,994,170 | 14,298,200 | reduced | -76.52 | ||
| MRUS | merus n v | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| NAMS | newamsterdam pharma company | 4.27 | 2,175,000 | 61,857,000 | unchanged | 0.00 | ||
| PCVX | vaxcyte inc | 0.44 | 175,000 | 6,303,500 | unchanged | 0.00 | ||
| PHVS | pharvaris n v | 2.35 | 1,363,200 | 34,011,800 | reduced | -6.29 | ||